Skip to main content
. 2022 Aug 4;27(11):907–918. doi: 10.1093/oncolo/oyac135

Figure 4.

Figure 4.

Median OS according to practice type (A), s-AML versus de-novo AML (B), presence or absence of venetoclax treatment schedule modifications (C), and presence or absence of venetoclax dose changes (D). Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; no., number; NR, not reached; OS, overall survival; s-AML, secondary acute myeloid leukemia.